Vaughan Nelson Investment Management L.P. purchased a new position in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,355 shares of the company’s stock, valued at approximately $2,042,000.
A number of other large investors have also modified their holdings of AZNCF. Balboa Wealth Partners purchased a new position in shares of AstraZeneca in the 1st quarter valued at approximately $238,000. Triad Wealth Partners LLC acquired a new stake in AstraZeneca in the 1st quarter worth approximately $386,000. Quotient Wealth Partners LLC purchased a new stake in AstraZeneca during the 1st quarter worth approximately $330,000. Park National Corp OH acquired a new stake in shares of AstraZeneca during the first quarter worth $14,462,000. Finally, Founders Financial Securities LLC acquired a new stake in shares of AstraZeneca during the first quarter worth $3,235,000. Hedge funds and other institutional investors own 40.87% of the company’s stock.
AstraZeneca Price Performance
Shares of AZNCF opened at $187.10 on Tuesday. The company’s fifty day moving average price is $187.10 and its 200-day moving average price is $186.10. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00.
AstraZeneca Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Further Reading
- Five stocks we like better than AstraZeneca
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
